title: Methamphetamine-induced neurotoxicity in BALB/c, DBA/2N and C57BL/6N mice.
abstract: Repeated administration of methamphetamine (METH; 2 and 4 mg/kg, s.c. four times every 2 h) caused hyperthermia and a dose-dependent depletion of striatal dopamine levels 3 days after the METH-treatment in both BALB/cAnNCrj (BALB) and DBA/2NCrj (DBA) mice, but these responses were lower in C57BL/6NCrj (C57BL) mice. An acute decrease of striatal dopamine levels 30 min after the last injection of METH (4 mg/kg) was observed in both BALB and DBA mice, while an increase in dopamine was observed in C57BL mice. Striatal 3-methoxytyramine levels were drastically increased in both DBA and C57BL mice after this same treatment. Moreover, pretreatment with the superoxide dismutase inhibitor, diethyldithiocarbamate (200 mg/kg, i.p.) exacerbated the METH (4 mg/kg)-induced striatal dopamine-depletion in BALB mice. In addition, pretreatment with an inhibitor of poly(ADP-ribose) polymerase, benzamide (160 mg/kg, s.c.), significantly attenuated the METH (4 mg/kg)-induced striatal dopamine depletion in both BALB and DBA mice. These results suggest that both BALB and DBA mice possess a higher sensitivity to the METH-induced striatal dopaminergic neurotoxicity compared to C57BL mice. In addition, the striatal dopaminergic neurons of BALB mice may be more vulnerable to METH-induced oxidative stress as compared to that in C57BL mice.
authors.affiliation: Department of Pharmacology, Nara Medical University, Kashihara, Japan. tkita@nmu-gw.cc.naramed-u.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Kita
authors.forename: S
authors.initials: S
authors.lastname: Paku
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
authors.forename: K
authors.initials: K
authors.lastname: Kubo
authors.forename: G C
authors.initials: GC
authors.lastname: Wagner
authors.forename: T
authors.initials: T
authors.lastname: Nakashima
mesh_terms: D000818:Animals; D000931:Antidotes / Q000494:pharmacology; D001549:Benzamides / Q000494:pharmacology; D001831:Body Temperature / Q000187:drug effects; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004050:Ditiocarb / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D008297:Male; D008694:Methamphetamine / Q000008:administration & dosage / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D012007:Rectum; D012701:Serotonin / Q000378:metabolism; D013045:Species Specificity; D013997:Time Factors
chemical_list: D000931:Antidotes; D001549:Benzamides; D018765:Dopamine Uptake Inhibitors; D012701:Serotonin; D008694:Methamphetamine; D006897:Hydroxyindoleacetic Acid; C037689:benzamide; D004050:Ditiocarb; D004298:Dopamine